{"name":"Clinuvel, Inc.","slug":"clinuvel-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Afamelanotide and NB-UVB Light","genericName":"Afamelanotide and NB-UVB Light","slug":"afamelanotide-and-nb-uvb-light","indication":"Erythropoietic protoporphyria (EPP)","status":"phase_3"}]}],"pipeline":[{"name":"Afamelanotide and NB-UVB Light","genericName":"Afamelanotide and NB-UVB Light","slug":"afamelanotide-and-nb-uvb-light","phase":"phase_3","mechanism":"Afamelanotide stimulates melanin production via alpha-melanocyte-stimulating hormone (α-MSH) receptor activation, which is then enhanced by controlled NB-UVB light exposure to increase skin pigmentation and photoprotection.","indications":["Erythropoietic protoporphyria (EPP)","X-linked protoporphyria (XLP)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-09","type":"earnings","source":"simplywall.st","summary":"A Look At Clinuvel Pharmaceuticals (ASX:CUV) Valuation After Softer Half Year Earnings Results - simplywall.st","headline":"A Look At Clinuvel Pharmaceuticals (ASX:CUV) Valuation After Softer Half Year Earnings Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPRElETWlnREZGMmFnQnRZcEc5cWNVZ09XcHNENzVselBRR3NJZno3U2oyZENvbS1vaU9TY3oyVkJwZHJ6LTNLNlpSMzMxemlNUmJrN0J1RnNqN2FTcmNjRWRBeEVETFI0SVI5VFhGWEtET1pBTEVaZ1hKTTRIX0I4TG01TWFvVktzZFVQZVlkeUUxSnlxUlJBdDdWYjdVWUJ5N1hHZ3ZuZnpONGswcVctanl0UGVybkhqX0lYUFEyRzlpWFE4WkVv?oc=5","date":"2026-02-26","type":"pipeline","source":"Morningstar","summary":"Clinuvel Shares Appear Undervalued as Sales in Core Product Continue to Grow - Morningstar","headline":"Clinuvel Shares Appear Undervalued as Sales in Core Product Continue to Grow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOMHI2VWtKVFhHajZqSXhiVUQ4STNwRHc5YnNnLU5zY1pfbEFlN1hrSjdhZzlzOWZMb2VqUnJZR2hnU1VNLUF3Z2RSV1dMcFhzOFQxeV9sZzJGVmVueEwyNWhRdnRRQWxpajFsQ0VaRFFVeDZjUEtpa2JmSkQzWUgyc0RIS2FES1RqeW5WTTlueHNEM1hScURiRVdYRHMtLTY0cmFXZ0hCVlNxZDR2NlctQkRxNzVGNXdESjRwYlhYaFJNTGZheDRTR3JQX3RPZkM3VGJsX3hvMVN0MGhwanJzbTFNcXpYVGxGbFlHS0M0UlNCeVMzM0VWUTVHSDh3dw?oc=5","date":"2026-01-11","type":"trial","source":"Proactive financial news","summary":"Clinuvel shares rise as company begins preclinical study of controlled-release injectable platform | ASX:CUV - Proactive financial news","headline":"Clinuvel shares rise as company begins preclinical study of controlled-release injectable platform | ASX:CUV","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOa1N4SE90S2RiZURfRzJ1Q0Z2Yjc5dGpSaGRmaDI0NHEtakI5cmV4NllNTlpBT0RFRHJyVV9IMERUVjF0T282SVZJTXdIWklTM05oOWhKUk04dzlOUGlDZjJManJXa0hvZWRpakJvNlJsQWZUd1JYWTZDM1B4LTFGdDJKSkhGNEE?oc=5","date":"2025-12-10","type":"pipeline","source":"Yahoo Finance","summary":"Clinuvel Pharmaceuticals (ASX:CUV) Is Up 6.2% After Expanding Singapore Peptide R&D Hub - Has The Bull Case Changed? - Yahoo Finance","headline":"Clinuvel Pharmaceuticals (ASX:CUV) Is Up 6.2% After Expanding Singapore Peptide R&D Hub - Has The Bull Case Changed?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-03","type":"pipeline","source":"businesswire.com","summary":"United States Vitiligo Forecast Report 2025: A $320+ Million Market by 2033 Featuring Incyte, BMS, Clinuvel Pharmaceuticals, Astellas Pharma, Baxter, Pfizer, Dr. Reddy's Laboratories - ResearchAndMark","headline":"United States Vitiligo Forecast Report 2025: A $320+ Million Market by 2033 Featuring Incyte, BMS, Clinuvel Pharmaceutic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNbHdDaUxBUGkxWXF3amJfaW12U3J1WFYwakExWmhhU0YzU05LWFBUWnhLSVdUaGlFc0liRlBaMUdpZ25oNTl4NDN4QnpMNHk1WnEzNTBpZFlLbEwyNHNWTHRzLXlXR2VMTlB1YTdaY183aVVwSF92NVpZdUxsT0NFZkNRUWMwRF84VnI3M2VpZldtcUtCQ09OSXd4ejQ?oc=5","date":"2025-09-28","type":"pipeline","source":"Yahoo Finance","summary":"CLINUVEL to advance novel pharmaceutical formulations in preclinical program - Yahoo Finance","headline":"CLINUVEL to advance novel pharmaceutical formulations in preclinical program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQaTRuN0FNWW9OcjdMWmx5N2xoSVVjNkdXLWhZc3Q3OWR4dkozOEV2N3hPRUFoYkpjbXN1Z01HSnkyQlBGMVlaNC15U1AyQlV4bGV2WmoxUmxwdnp0d0ZiREdQbmIzdTIyV01BWjhFdzNnLTFfd25GblNLb3htUjh1MERLT1ptNmkzbTBoWEtSWnVKVGhvTzg0cTF1MWhwTmJNaXFINUtyMXBEWGR0?oc=5","date":"2025-09-23","type":"pipeline","source":"The Motley Fool Australia","summary":"Why Clinuvel, DroneShield, Nuix, and Telix shares are storming higher today - The Motley Fool Australia","headline":"Why Clinuvel, DroneShield, Nuix, and Telix shares are storming higher today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNVWE3VjRUVmtGaHlJS1dGU2VEQlhYWXlVR1R3alZpX3p0Y1AtNDd1SVUwcF9OOWVVdEE3MG1lal8yOTJ5RVVqZXRTMEVFcHVUelcwRUVneUtqdWg1ZFNQanV1SWdESHFkRlhCaU9MZ3F2bnQyYm84ZjF1QlJSb2U3UlNLT0hvS01NbWc?oc=5","date":"2025-09-06","type":"earnings","source":"Yahoo Finance","summary":"Why Clinuvel Pharmaceuticals (ASX:CUV) Is Up 5.9% After Strong Earnings and NASDAQ ADR Expansion Plans – And What's Next - Yahoo Finance","headline":"Why Clinuvel Pharmaceuticals (ASX:CUV) Is Up 5.9% After Strong Earnings and NASDAQ ADR Expansion Plans – And What's Next","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2025-09-03","type":"earnings","source":"simplywall.st","summary":"Why Clinuvel Pharmaceuticals' (ASX:CUV) Earnings Are Better Than They Seem - simplywall.st","headline":"Why Clinuvel Pharmaceuticals' (ASX:CUV) Earnings Are Better Than They Seem","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-29","type":"earnings","source":"simplywall.st","summary":"Clinuvel Pharmaceuticals Full Year 2025 Earnings: Misses Expectations - simplywall.st","headline":"Clinuvel Pharmaceuticals Full Year 2025 Earnings: Misses Expectations","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNMjZaQTZrRUtBdWxxTzY0Vl94Uk5SRlVtTW16dFRtY2swVE9FNDRCbVZBbTgtQnNmckhDMVJCOEJTWkRCODNscU1VSzROVWZrdExwN2pzQWNDM0x0UGstRTFQZHZIZjl0UThiVGlJVWllekpPZnBfQzVOczVWTzJPdDQ5b1I1Ukxlbk5DNjNxWFpYWW80MVJUY2Vn?oc=5","date":"2025-08-29","type":"earnings","source":"Yahoo Finance","summary":"Clinuvel Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance","headline":"Clinuvel Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPdlFSZ0RCREhFWUNNVUl5QWM2VlJqZW5KcVhOdFRwTzZvb3VWZEhiMmRuSjRwcU91YlF3Z2p4SHRMRkdIOE1fYTZELXIyS1FpU1o3S01OSk5zV2xudVpFcE1tYm9WanlEb2xXV2tLY2NESWtWbGpPeWlfLVNZbmxoVXJVUE9VdXRibllMcUc4Nmc?oc=5","date":"2025-07-06","type":"pipeline","source":"Yahoo Finance","summary":"Clinuvel Pharmaceuticals Limited's (ASX:CUV) top owners are individual investors with 60% stake, while 23% is held by institutions - Yahoo Finance","headline":"Clinuvel Pharmaceuticals Limited's (ASX:CUV) top owners are individual investors with 60% stake, while 23% is held by in","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}